The European Commission granted marketing authorisation for Adcomfo (omalizumab), a biosimilar referencing Xolair, on 12 November 2026. The product was developed by Kashiv BioSciences in collaboration with Alvotech. The decision followed a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), adopted on 17 September 2026, and expands the product’s regulatory presence in European markets.
Adcomfo is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to immunoglobulin E (IgE), thereby reducing the amount of free IgE available to trigger the allergic cascade.
Amneal Pharmaceuticals acquired Kashiv BioSciences in August 2026. In Europe, Advanz Pharma Limited holds the marketing authorisation and regional commercialisation rights through its partnership with Alvotech.
Three approved therapeutic indications
The European authorisation covers three indications:
- Severe persistent allergic asthma: add-on treatment for eligible adults, adolescents and children aged six years and older.
- Chronic rhinosinusitis with nasal polyps (CRSwNP): add-on treatment with intranasal corticosteroids for adults with severe CRSwNP whose condition is inadequately controlled by intranasal corticosteroid therapy.
- Chronic spontaneous urticaria (CSU): add-on treatment for adults and adolescents aged 12 years and older who have an inadequate response to H1 antihistamines.
According to Amneal, the authorised presentations include 75 mg, 150 mg and 300 mg pre-filled syringes, as well as 75 mg and 150 mg pre-filled autoinjector pens.
Clinical evidence supporting biosimilarity
The regulatory application was supported by analytical, pharmacokinetic and clinical data demonstrating biosimilarity to the reference medicine, Xolair.
The clinical development programme included two principal studies.
The first was a randomised, double-blind, three-arm, single-dose comparative study in healthy adult volunteers. It compared the pharmacokinetic, pharmacodynamic, safety and immunogenicity profiles of ADL-018 with those of the EU-authorised reference product.
The second was a confirmatory, randomised, double-blind, multicentre study involving 600 patients with chronic spontaneous urticaria. The study met its primary efficacy endpoint, demonstrating equivalent efficacy based on the change from baseline in the weekly Itch Severity Score (ISS) at Week 12. Safety profiles were also reported to be comparable between treatment groups.
Across the clinical studies, the most frequently reported adverse reactions included headache, fever, upper abdominal pain, dizziness, joint pain and injection-site reactions. Most of these reactions were classified as mild to moderate.
European and US regulatory status
The European Commission’s decision follows the positive CHMP opinion adopted on 17 September 2026. The product had previously received UK marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) in March 2026.
The European marketing authorisation applicant is Advanz Pharma Limited, which also holds regional commercialisation rights under its partnership with Alvotech.
In the United States, Amneal reports that its Biologics License Application (BLA) for the proposed omalizumab biosimilar remains under review by the US Food and Drug Administration (FDA).
The European authorisation represents another regulatory milestone for the omalizumab biosimilar programme and expands the range of biologic medicines available in Europe.


